Temoside 20

Temoside 20 is a specialized oral cytotoxic chemotherapy agent containing 20 mg of Temozolomide, manufactured by Cipla. Classified as an alkylating antitumor agent, it is primarily indicated for treating specific forms of aggressive brain tumors, such as newly diagnosed glioblastoma multiforme and refractory anaplastic astrocytoma. It works by damaging cancer cell DNA, which prevents cell replication and halts tumor growth. Typically administered on an empty stomach to minimize side effects, Temoside 20 serves as a critical therapeutic intervention managed strictly under an oncologist’s guidance to optimize patient survival outcomes.